Bravelle 75 IU (urofollitropin for injection, purified) For Subcutaneous or Intramuscular Injecti...
FDA Drug Recall #D-0015-2016 — Class III — September 9, 2015
Recall Summary
| Recall Number | D-0015-2016 |
| Classification | Class III — Low risk |
| Date Initiated | September 9, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Ferring Pharmaceuticals Inc |
| Location | Parsippany, NJ |
| Product Type | Drugs |
| Quantity | 32,341 vials |
Product Description
Bravelle 75 IU (urofollitropin for injection, purified) For Subcutaneous or Intramuscular Injection Only, 1 Carton (contains 5 single dose vials of Bravelle, 5 single dose vials of 0.9% Sodium Chloride Inj., USP, 2 mL, and 5 Q-Cap Vial Adaptors) , Rx Only, Manufactured for: Ferring Pharmaceuticals, Inc. Parsippany, NJ 07054, By: Ferring Gmbh, Kiel Germany, NDC 55566-8505-6
Reason for Recall
Subpotent Drug
Distribution Pattern
Nationwide
Lot / Code Information
Lot #'s: K11813A-1, K11813A-2, Exp 01/16; K11813B-1, K11813C-1, Exp 04/16; K13031A-1, K13031B-1, K13031B-2, Exp 05/16 additional lots added: H14942A-1, H14941A-2. H18815A-1, H15815B-1, H15815SMA-1, H16998A-1, H16998SMA-1, K10008A-1, K10008A-2, K11813A-2, K11813B-1, K11813C-1, K13031A-1, K13031B-1, K13031B-2, K13503SMA-1, K13503A-1, K13503B-1, K13512A-1, K13512A-2, K1392A-1, K13921A-2, K13921B-1, K14616A-1, K14616A-2, K15917A-1, K15917SMA-1, K15917SMA-2, K17006AA, K18201AA, K18202AA, L10403AA, L10403AB, L10840AA, L10992AA
Other Recalls from Ferring Pharmaceuticals Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0879-2023 | Class II | Endometrin (progesterone) Vaginal Insert 100mg,... | Jun 12, 2023 |
| D-0318-2021 | Class II | ZOMA-Jet 10 Demonstration Kit, Needle-free deli... | Mar 11, 2021 |
| D-0317-2021 | Class II | ZOMA-Jet 5 Demonstration Kit, Needle-free deliv... | Mar 11, 2021 |
| D-0299-2021 | Class III | Menopur 75 IU, (menotropins for injection), pac... | Mar 2, 2021 |
| D-1506-2020 | Class I | STIMATE (desmopressin acetate) Nasal Spray1.5 m... | Jul 21, 2020 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.